Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. sime-lmt

SIME-LMT

Development of a digital diagnostics rapid Lung Maturity Test (LMT) for premature infants, to assist neonatologists in the diagnosis of Respiratory Distress Syndrome at birth

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 SIME-LMT project word cloud

Explore the words cloud of the SIME-LMT project. It provides you a very rough idea of what is the project "SIME-LMT" about.

diagnosis    refining    stay    life    optimal    complexity    quick    bodily    lmt    market    infant    mechanical    opportunity    worldwide    validation    innovation    neonatologists    prevented    diagnostics    ventilation    digital    standard    software    tests    sime    diagnostic    biological    total    valuation    revenue    2000    patient    4bn    cloud    annum    nicus    digitising    business    chemometrics    faster    accuracy    protocol    laboratory    driving    point    treatment    days    platform    distress    predicts    hospital    fluid    neonatal    lung    providers    intensive    95    approx    rds    minutes    chemistry    reduce    data    preventative    improves    initial    5m    syndrome    company    60    sciences    small    60m    oxygen    clinical    outcomes    strategy    respiratory    aligned    reduces    expertise    400    gt    care    profit    savings    samples    birth    generating    representing    risk    healthcare    375m    prototype    916    attaining    maturity    time   

Project "SIME-LMT" data sheet

The following table provides information about the project.

Coordinator		 SIME DIAGNOSTICS LIMITED 

Organization address
address: Stevenage Bioscience Catalyst, Gunnel Wood Road
city: STEVENAGE
postcode: SG1 2FX
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country United Kingdom [UK]
 Project website http://www.simelmt.com
 Total cost 3˙417˙674 €
 EC max contribution 2˙864˙455 € (84%)
 Programme 1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-04-01   to  2017-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SIME DIAGNOSTICS LIMITED UK (STEVENAGE) coordinator 2˙864˙455.00

Map

 Project objective

SIME LMT will develop a simple digital, software and cloud-based diagnostic test to analyse very small samples of bodily fluid at point of care that predicts the risk of an infant developing Respiratory Distress Syndrome (RDS) within 10 minutes of birth. The platform will offer neonatologists more control through greater accuracy and faster results so they can deliver optimal patient care and improve clinical outcomes. Such technology has not been deployed before in healthcare diagnostics because of the complexity of the required knowledge and expertise in the field of chemometrics. RDS can only be prevented by a quick diagnosis of lung maturity and treatment at birth.

We have developed a working prototype test that measures within 95% of the established laboratory and chemistry validation methods. We are currently refining the method in a pre-clinical test which will provide test validation data and demonstrate that the test improves clinical outcomes and enables change in clinical practice from the current treatment standard to a preventative treatment protocol which reduces RDS i.e. generating Level 4 – Level 1 evidence.

Our initial target market is the NICUs: 2000 in the US and 1,400 in the EU, where there is an estimated market of 916,000 tests and a revenue potential of approx. €375m per annum. SIME Diagnostics also has the potential to reduce neonatal intensive care treatment including mechanical ventilation by 60%, less time on oxygen and hospital stay by 10 days. The overall savings opportunity has been estimated to be more than €3.4bn total, and €1.5m per 100 cases representing a cost savings and profit making opportunity for healthcare providers worldwide. The project is well aligned with our business growth strategy which is aimed at growing the business through digitising biological information, driving innovation in life sciences and healthcare. Attaining level 1 clinical evidence will increase company valuation to >€60m.

 Deliverables

List of deliverables.
Approved publication Documents, reports 2019-05-30 11:42:35
Project Specific Website Other 2019-05-30 11:42:34
Production tooling, sample batch (spectrometers) Demonstrators, pilots, prototypes 2019-05-30 11:42:35

Take a look to the deliverables list in detail:  detailed list of SIME-LMT deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SIME-LMT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SIME-LMT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.;H2020-EU.2.3.1.)

PREPARE (2016)

Preventing Respiratory Events through Proactive Assessment of Respiratory Effort

Read More  

ADVANTAGE (2015)

ADvanced Validation of A Novel TB Active disease diagnostic to address Global unmet needs: a European consortium approach

Read More  

SIME-LMT (2015)

Development of a digital diagnostics rapid Lung Maturity Test (LMT) for premature infants, to assist neonatologists in the diagnosis of Respiratory Distress Syndrome at birth

Read More